​

Context Therapeutics Stock (NASDAQ:CNTX)

ForecastOwnershipFinancialsChart
Context Therapeutics by TradingView

Previous Close

$0.24

52W Range

$0.21 - $3.62

50D Avg

$0.36

200D Avg

$1.49

Market Cap

$21.99M

Avg Vol (3M)

$1.54M

Beta

1.72

Div Yield

-

CNTX Company Profile

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

15

IPO Date

Oct 20, 2021

Website

CNTX Performance

CNTX Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-39.70M$-29.92M$-25.07M
Net Income$-36.12M$-26.73M$-23.96M
EBITDA$-39.70M$-29.91M$-25.06M
Basic EPS$-0.38$-0.46$-1.50
Diluted EPS$-0.38$-0.46$-1.50

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
IFRXInflaRx N.V.
IMAImageneBio Inc
OVIDOvid Therapeutics Inc.
STTKShattuck Labs, Inc.
WHWKWhitehawk Therapeutics Inc
MGNXMacroGenics, Inc.
CLNNClene Inc.
KLRSKalaris Therapeutics Inc
CNTBConnect Biopharma Holdings Limited
ORMPOramed Pharmaceuticals Inc.